ClinicalTrials.gg
CompletedNCT06024915Updated Dec 12, 2025

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

A Phase 1 interventional study of TQ05105 tablets and Itraconazole capsule in Myelofibrosis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited — 3 open to participants now, 5 under way, none of them phase 3. Primary Myelofibrosis · Sino Biopharmaceutical Limited.

Enrollment
4th of 10
40 · median 28
Started
2023
with 1 other
Phase 1
7 of 10
1 open now
Registered
2nd of 10
by date

Among the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, this one is the 4th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 2nd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of signing the , males or females between 18 and 45 years of age;
  • Female weight ≥ 45 kg, male weight ≥ 50 kg, with a (BMI) between 19 and 26 kg/m2.
  • Subjects in good health, as determined by a medical history, vital signs, physical examination, 12-lead (ECG) and clinical laboratory evaluations;
  • Subjects can comply with the study procedures, voluntarily participate in the study, and sign the informed consent in person.

Exclusion criteria

Exclusion Criteria:

  • Subjects: preexisting or existing circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic disorders or abnormalities, or related chronic or acute diseases, the investigator assesses that it is not appropriate to participate in the trial;
  • Subjects with Systemic/local acute infection before taking the study drug;
  • Subjects who have a history of specific allergies, or allergic conditions (such as allergies to two or more drugs, environments, or foods), or are known to be allergic to components or analogs of the study drug;
  • Subjects who have difficulty in swallowing or have any gastrointestinal disorder that affects drug absorption at the time of screening;
  • Subjects who cannot receive venous indwelling needle for blood sample collection;
  • Subjects who drank regularly in the 6 months prior to first dosing, such as those who drank more than 14 units of alcohol per week or who had a positive alcohol breath test at the time of screening;
  • Subjects who had a history of major surgery, or had taken the study drug, or had participated in other drug clinical trials within 3 months prior to initial dosing;
  • Subjects who donated blood or lost significant amounts of blood within 3 months prior to initial dosing;
  • Subjects who had used drugs within 3 months prior to first dosing, or tested positive for drugs, or had a history of drug abuse within 5 years prior to screening;
  • Subjects who smoked more than 5 cigarettes per day in the 3 months prior to initial dosing or who could not stop using any tobacco products during the trial;
  • Subjects who consumed excessive amounts of tea, coffee, and/or caffeinated beverages daily in the 30 days prior to initial dosing;
  • Subjects who have used any drug that inhibits or induces liver metabolism of the drug in the 30 days prior to initial dosing;
  • Subjects who have taken any prescription, over-the-counter, herbal, or health product in the 14 days prior to initial dosing;
  • Subjects who have taken a special diet or other factors affecting drug absorption, distribution, metabolism, or excretion within 7 days prior to initial dosing;
  • Subjects who ingested chocolate, any caffeinated, or xanthine-rich food or drink 48 hours before first dosing;
  • Subjects who have special dietary requirements and cannot follow a uniform diet;
  • Female subjects of ;
  • Subjects judged by the investigator to be unsuitable to participate.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Itraconazole drug-durg interaction (DDI)

    Itraconazole capsule: 0.2g once daily on Days 2 to Day 5; TQ05105 tablets: single oral dose on Days 1 and Day 5.

    Drug: TQ05105 tablets · Drug: Itraconazole capsule

  • Experimental
    Rifampicin DDI

    Rifampicin Capsule: 0.6g once daily on Days 2 to Day 9; TQ05105 tablets: single oral dose on Days 1 and Day 9.

    Drug: TQ05105 tablets · Drug: Rifampicin Capsule

Interventions

  • TQ05105 is a Janus kinase 2 (JAK2) inhibitor.

  • DrugItraconazole capsule

    Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).

  • DrugRifampicin Capsule

    Rifampicin is a strong inducer of CYP3A.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax)

    Maximum plasma drug concentration after administration.

    Time frame: Up to 10 days.

  2. Time to reach Cmax (Tmax)

    Time to reach the maximum plasma concentration after administration.

    Time frame: Up to 10 days.

  3. Elimination half-life (t1/2)

    The elimination half-life (t1/2) after oral dose of TQ05105 tablets and Itraconazole capsule.

    Time frame: Up to 6 days.

Secondary outcomes

  1. Occurrence of adverse events (AE)

    Including all adverse events (AE) and serious adverse events (SAE).

    Time frame: Up to 30 days.

07

Study locations

1 site
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jan 2024, 4 months.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Sep 6, 2023
StartActual
Sep 21, 2023
Primary completionActual
Jan 29, 2024
CompletionActual
May 6, 2024
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06024915
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Sep 21, 2023
Primary completion
Jan 29, 2024
Completion
May 6, 2024
Last update
Dec 12, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JAK2 Inhibitor TQ05105

Start the discussion